How to improve access to cancer medicines in low and middle-income countries
Poor healthcare systems are a major barrier to patients accessing life-saving cancer medicines. Public-private partnerships could ensure better access.
BSc (Hons) in Economics, Computing and Statistics, University of Bath, UK; MBA (Hons); 2003, Executive General Management programme, Harvard Business School. 2009, Chief Executive Officer, UICC, based in Geneva. UICC unites the cancer community to reduce the global cancer burden, to promote greater equity, and to integrate cancer control into the world health and development agenda. Its rapidly increasing membership base of over 1,000 organizations in 162 countries features the world’s major cancer societies, ministries of health and patient groups and includes influential policy-makers, researchers and experts in cancer prevention and control. UICC also boasts more than 50 strategic partners. Former Chair, NCD Alliance, a coalition of around 2,000 organizations working on non-communicable diseases, which include cancer, diabetes, heart, respiratory, mental and neurological diseases. Recipient of honours and awards, including: Honorary Doctorate in International Relations, University for Business and International Studies, Geneva (2014); Honorary Doctorate in Health, Bath University, UK (2015); CEO of the year, International and European Association conference, Associations Network (2015).